20240009116. DRUG DELIVERY SYSTEM COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND A PROGESTOGENIC COMPOUND AND METHODS FOR MANUFACTURING simplified abstract (Bayer OY)

From WikiPatents
Jump to navigation Jump to search

DRUG DELIVERY SYSTEM COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND A PROGESTOGENIC COMPOUND AND METHODS FOR MANUFACTURING

Organization Name

Bayer OY

Inventor(s)

Harri Jukarainen of Kuusisto (FI)

Jyrki Pihlaja of Paimio (FI)

Savante Holmberg of Turku (FI)

Tuula Valo of Turku (FI)

Anu-Liisa Honka of Turku (FI)

Jenny Hollaender of Parainen (FI)

DRUG DELIVERY SYSTEM COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND A PROGESTOGENIC COMPOUND AND METHODS FOR MANUFACTURING - A simplified explanation of the abstract

This abstract first appeared for US patent application 20240009116 titled 'DRUG DELIVERY SYSTEM COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND A PROGESTOGENIC COMPOUND AND METHODS FOR MANUFACTURING

Simplified Explanation

The abstract of this patent application describes a method for fabricating drug-containing intrauterine systems using 3D printing technique, specifically fused deposition modelling (FDM™). The drug, indomethacin, is incorporated within the entire backbone of the medical device by preparing drug-loaded poly-caprolactone (PCL) based filaments with different drug contents (5-40 wt %).

  • The patent application proposes using 3D printing, specifically FDM™, to fabricate drug-containing intrauterine systems.
  • The drug-loaded filaments are made from poly-caprolactone (PCL) and indomethacin.
  • Different drug contents (5-40 wt %) are used to prepare the filaments.
  • The drug is incorporated within the entire backbone of the medical device.
  • The purpose of this innovation is to provide a method for fabricating drug-containing intrauterine systems using 3D printing, which allows for precise drug delivery and customization.

Potential applications of this technology:

  • Manufacturing drug-containing intrauterine systems with precise drug delivery capabilities.
  • Customizing drug-loaded medical devices for individual patients.
  • Improving the effectiveness and convenience of drug delivery in intrauterine systems.

Problems solved by this technology:

  • Traditional methods of fabricating drug-containing intrauterine systems may not allow for precise drug delivery or customization.
  • This technology solves the problem of limited drug incorporation within the medical device by incorporating the drug within the entire backbone.
  • It also solves the problem of limited customization by using 3D printing to fabricate personalized drug-loaded devices.

Benefits of this technology:

  • Precise drug delivery: The drug is incorporated within the entire backbone, allowing for controlled and targeted drug release.
  • Customization: 3D printing enables the fabrication of personalized drug-loaded devices, tailored to individual patients' needs.
  • Improved convenience: Drug-containing intrauterine systems can be manufactured with the desired drug content, eliminating the need for separate drug administration.


Original Abstract Submitted

a further object of the invention is to fabricate drug-containing t-intrauterine systems (ius) with the drug incorporated within the entire backbone of the medical device by using 3d printing technique, based on fused deposition modelling (fdm™). indomethacin was used to prepare drug-loaded poly-caprolactone (pcl)-based filaments with different drug contents 5-40 wt %, namely 5%, 15% and 30% wt %:of indomethacin.

Retrieved from "http://wikipatents.org/index.php?title=20240009116._DRUG_DELIVERY_SYSTEM_COMPRISING_A_NON-STEROIDAL_ANTI-INFLAMMATORY_(NSAID)_AND_A_PROGESTOGENIC_COMPOUND_AND_METHODS_FOR_MANUFACTURING_simplified_abstract_(Bayer_OY)&oldid=27148"